港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

高瓴概念

470.710

-8.991-1.87%

漲家數：23

跌家數：29

平家數：3

市盈率：- -

高：482.424

開：479.701

低：469.662

收：479.701

資料載入中...

總覽新聞資訊

即時零售大戰前傳：互聯網健康的十年“三國殺”

华尔街见闻

恆瑞醫藥(600276.SH)：SHR-1316(sc)注射液獲得藥物臨牀試驗批准通知書

翰森製藥(03692)：阿美樂®(甲磺酸阿美替尼片)第四項適應症獲國家藥品監督管理局簽發藥品註冊證書

翰森製藥：阿美樂®(甲磺酸阿美替尼片)第四項適應症獲國家藥品監督管理局簽發藥品註冊證書

翰森製藥(03692.HK)阿美樂第四項適應症獲發藥品註冊證書

阿斯达克财经

歸創通橋(02190)5月9日斥資95.85萬港元回購5萬股

東方雨虹：因金科股份存在欠款已接受其持有的部分金科服務股份質押

“太平洋醫藥”君實生物公司點評：拓益收入同比增長 46%，關注 DKK1 胃腸道腫瘤早期數據

時代天使新品上市有望進一步夯實競爭優勢，長期發展動能強勁

Lorenzo 戰略升級，專注 CeFi 金融產品代幣化與真實收益拓展

“科企專線”來了！創新藥企或受益

中国商报网

高視醫療附屬公司新型人工晶狀體植入系統獲批醫療器械註冊證

重慶市涪陵區市場監管局開展醫療器械網售環節專項檢查

中国质量新闻网

復星醫藥子公司獲美國FDA批准開展AGA治療臨牀試驗

高視醫療(02407)：人工晶狀體植入系統獲得中國醫療器械註冊證

高視醫療(02407.HK)人工晶狀體植入系統獲中國醫療器械註冊證

阿斯达克财经

分析師：美英達成貿易協議股市修復出現曙光

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1583/news?page=11"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"高瓴概念","latestPrice":470.7096,"timestamp":1747123711788,"preClose":479.70102,"halted":0,"volume":457379627,"delay":0,"changeRate":-0.018744,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-8.991425,"latestTime":"05-13 16:00:00","open":479.70102,"high":482.42447,"low":469.6616,"amount":14516179954,"amplitude":0.026606,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1747186200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1747099800000,1747108800000],[1747112400000,1747123200000]],"pbRate":2.269203,"peRate":21.770339,"turnoverRate":0.003175,"increases":23,"decrements":30,"flats":1,"marketCap":2664799825984,"floatMarketCap":2087029888320},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":482.42447,"amplitude":0.026606,"preClose":479.70102,"low":469.6616,"pbRate":"2.269203","latestPrice":470.7096,"volume":457379627,"delay":0,"open":479.70102,"prevYearClose":446.93042,"prevWeekClose":480.539,"prevMonthClose":473.358,"prevQuarterClose":505.776,"fiveDayClose":485.703,"twentyDayClose":463.61,"sixtyDayClose":470.714,"secType":"PLATE","market":"HK","turnoverRate":0.003175,"peRate":21.770339,"marketCap":2664799825984,"floatMarketCap":2087029888320,"timestamp":1747123711788,"nameCN":"高瓴概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":23,"down":29,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:11,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534106420","title":"即時零售大戰前傳：互聯網健康的十年“三國殺”","url":"https://stock-news.laohu8.com/highlight/detail?id=2534106420","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534106420?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 18:24","pubTimestamp":1746786254,"startTime":"0","endTime":"0","summary":"互要流量","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/80a4ddb7-699e-49c8-b5bb-3d8b9af64cea.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/80a4ddb7-699e-49c8-b5bb-3d8b9af64cea.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3746786","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3746786","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["LU0181495838.USD","LU1328277881.USD","ALBmain","LU1046422090.SGD","LU0890818403.SGD","BK1583","LU1720051108.HKD","LU2125910500.SGD","LU0315179316.USD","LU0651946864.USD","00241","LU0871576103.HKD","LU0531971595.HKD","09939","LU2257852520.SGD","LU0128525689.USD","LU1282651121.HKD","LU1201861165.SGD","06618","BK1515","LU0594300179.USD","BK4524","LU1044876610.USD","LU1808992512.USD","03690","89988","BK1584","HBBD.SI","LU0700851271.USD","BK4579","LU0348827113.USD","LU1675838814.USD","LU0140636845.USD","LU0359201885.HKD","86618","MPNGY","LU2242644610.SGD","METmain","89618","LU0819123356.HKD","LU0231483743.USD","LU2097828474.EUR","LU0463099449.HKD","BK4504","HMTD.SI","LU0029875118.USD"],"gpt_icon":1},{"id":"2534177637","title":"恆瑞醫藥(600276.SH)：SHR-1316(sc)注射液獲得藥物臨牀試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177637","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177637?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:55","pubTimestamp":1746784534,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-1316(sc)注射液的《药物临床试验批准通知书》，将于近期开展临床试验。具体为SHR-1316(sc)联合卡铂和依托泊苷一线治疗广泛期小细胞肺癌中的药代动力学、安全性、耐受性及疗效的开放、多中心Ⅰ期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","LU0405327494.USD","BK1583","03347","LU2488822045.USD","BK0196","BK0188","BK0012","BK1576","LU0405327148.USD","LU1328615791.USD","BK0028","LU2328871848.SGD","LU1969619763.USD","BK0060","BK0239","600276","LU1064131003.USD","LU1064130708.USD","BK1141","LU2148510915.USD"],"gpt_icon":0},{"id":"2534177653","title":"翰森製藥(03692)：阿美樂®(甲磺酸阿美替尼片)第四項適應症獲國家藥品監督管理局簽發藥品註冊證書","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177653","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177653?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:55","pubTimestamp":1746784500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，本集团创新药阿美乐®(甲磺酸阿美替尼片)获中国国家药品监督管理局(NMPA)签发的药品注册证书，批准增加“用于II-IIIB期具有表皮生长因子受体(“EGFR”)外显子19缺失或外显子21(L858R)置换突变的成人非小细胞肺癌“NSCLC”)患者的治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐®获批的第四项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","BK1589","BK1191","BK1583"],"gpt_icon":0},{"id":"2534999483","title":"翰森製藥：阿美樂®(甲磺酸阿美替尼片)第四項適應症獲國家藥品監督管理局簽發藥品註冊證書","url":"https://stock-news.laohu8.com/highlight/detail?id=2534999483","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534999483?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:53","pubTimestamp":1746784413,"startTime":"0","endTime":"0","summary":"格隆汇5月9日丨翰森制药发布公告，集团创新药阿美乐获中国国家药品监督管理局签发的药品注册证书，批准增加“用于II-IIIB期具有表皮生长因子受体外显子19缺失或外显子21置换突变的成人非小细胞肺癌“NSCLC”）患者的治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐获批的第四项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917533394f19c65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917533394f19c65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03692","BK1583","BK1589"],"gpt_icon":0},{"id":"2534558177","title":"翰森製藥(03692.HK)阿美樂第四項適應症獲發藥品註冊證書","url":"https://stock-news.laohu8.com/highlight/detail?id=2534558177","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534558177?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:50","pubTimestamp":1746784200,"startTime":"0","endTime":"0","summary":"翰森制药(03692.HK) 公布，创新药阿美乐获国家药品监督管理局签发的药品注册证书，批准增加“用于II-IIIB期具有表皮生长因子受体外显子19缺失或外显子21(L858R)置换突变的成人非小细胞肺癌患者的治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐获批的第四项适应症。阿美乐是中国首个原研三代EGFR-TKI创新药，此前已于中国获批三项适应症。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-09 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1438988/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","03692","BK1191","BK1589"],"gpt_icon":0},{"id":"2534171299","title":"歸創通橋(02190)5月9日斥資95.85萬港元回購5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2534171299","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534171299?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:37","pubTimestamp":1746783453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)发布公告，于2025年5月9日斥资95.85万港元回购股份5万股，每股回购价格为18.86-19.82港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1587","BK1100","02190","BK1574"],"gpt_icon":0},{"id":"2534849177","title":"東方雨虹：因金科股份存在欠款已接受其持有的部分金科服務股份質押","url":"https://stock-news.laohu8.com/highlight/detail?id=2534849177","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534849177?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:31","pubTimestamp":1746783076,"startTime":"0","endTime":"0","summary":"证券之星消息，东方雨虹05月09日在投资者关系平台上答复投资者关心的问题。已经超过24年净利润200%了东方雨虹董秘：您好，因金科股份对公司存在欠款，公司作为其债权人，已接受金科股份将其持有的部分金科服务股份质押给我司。目前该部分质押股份尚未过户至我公司名下，公司尚未对其进行处置。公司未来如有相关计划，将严格按照深圳证券交易所的规定及时履行信息披露义务。感谢您对东方雨虹的关注！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509173642a6d8e2dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509173642a6d8e2dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1542","09666","BK1258","BK1583","BK1229"],"gpt_icon":0},{"id":"2534991171","title":"“太平洋醫藥”君實生物公司點評：拓益收入同比增長 46%，關注 DKK1 胃腸道腫瘤早期數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2534991171","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534991171?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:22","pubTimestamp":1746782527,"startTime":"0","endTime":"0","summary":"拓益销售收入保持高增速，公司运营效率显著提升，在手现金 30 亿元。2025 年第一季度公司实现收入 5 亿元， 其中，核心产品特瑞普利单抗于国内市场实现销售收入 4.47 亿元。研发费用 3.51 亿元，同比增加 26.89%；管理费用 0.97 亿元，同比减少 21.32%。拓益国内获批 12 项适应症，国际化布局进展顺利。截止目前，拓益已于国内获批 12 项适应症，10 项适应症纳入国家医保目录，其中 4 项为医保独家适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917245897544f69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917245897544f69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","09939","BK1161","BK1515","BK1583","BK1574"],"gpt_icon":0},{"id":"2534483943","title":"時代天使新品上市有望進一步夯實競爭優勢，長期發展動能強勁","url":"https://stock-news.laohu8.com/highlight/detail?id=2534483943","media":"国金证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534483943?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:16","pubTimestamp":1746782176,"startTime":"0","endTime":"0","summary":"截至2024年底，时代天使在中国市场完成了21.87万例隐形矫治案例，同比增长3.2%，但收入同比略有下降。预计随着防龋齿矫治器的全面上市，公司将巩固其市场地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509173146a477f2cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509173146a477f2cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1100","BK1587","BK1583","BK1593","06699"],"gpt_icon":0},{"id":"2534617651","title":"Lorenzo 戰略升級，專注 CeFi 金融產品代幣化與真實收益拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2534617651","media":"foresightnews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534617651?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:03","pubTimestamp":1746781380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://foresightnews.pro/foresightnews/news/detail/72414","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"foresightnews_live","symbols":["LU0642271901.SGD","LU0353189763.USD","LU2360107325.USD","BK4551","BK4588","LU2264538146.SGD","SG9999015945.SGD","SG9999018865.SGD","SG9999018857.SGD","LU1983260115.SGD","SGXZ31699556.SGD","LU1064131342.USD","BK4535","SG9999015986.USD","SG9999014880.SGD","IE00BZ199S13.USD","LU0006306889.USD","BK1583","BK4503","LU0127658192.USD","LU1988902786.USD","BK4505","IE00B19Z3581.USD","09983","BK1229","SGXZ81514606.USD","SGXZ99366536.SGD","LU0082616367.USD","LU1861219969.SGD","BK4230","LU1814569148.SGD","BK1542","BK4585","SG9999014906.USD","IE00BFMHRM44.USD","SGXZ51526630.SGD","UBER","LU1861214812.USD","LU1316542783.SGD","LU0353189680.USD","SG9999014898.SGD","SG9999017495.SGD","BK4022","SG9999014914.USD","GB00BDT5M118.USD","SG9999015978.USD","159940","IE0002270589.USD","LU2087625088.SGD","LU0719512351.SGD"],"gpt_icon":0},{"id":"2534071480","title":"“科企專線”來了！創新藥企或受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2534071480","media":"中国商报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534071480?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:58","pubTimestamp":1746781107,"startTime":"0","endTime":"0","summary":"业内人士认为，“科企专线”是继“18A规则”后资本市场对生物科技公司释放的又一个利好信号。因此，上市对创新药企来说至关重要。未盈利的创新药企有望受益此前，“生物科技公司”在港交所申请上市遵循香港《上市规则》中的第18A章，业内称“18A规则”。有数据显示，截至5月7日，经“18A规则”在港股上市的创新药械企业已经累计达到65家。头部港股创新药公司受益于出海成果放量，营收和利润稳步增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917262094f195fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917262094f195fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","02359","02269","BK1583","BK1574","LU2328871848.SGD","01801","06978","BK1161","LU1969619763.USD","09926","BK1589"],"gpt_icon":0},{"id":"2534517553","title":"高視醫療附屬公司新型人工晶狀體植入系統獲批醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2534517553","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534517553?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:51","pubTimestamp":1746780712,"startTime":"0","endTime":"0","summary":"5月9日，高视医疗（02407）发布公告，近日公司全资附属公司高视泰靓医疗科技有限公司的“人工晶状体植入系统”已获得由广东省药品监督管理局批准的医疗器械注册证。该注册证编号为粤械注准20252160605，主要适用于微小切口白内障手术中的人工晶状体植入手术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505093400638738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09996","BK1100","BK1222","BK1583","09997","02407","BK1574"],"gpt_icon":0},{"id":"2534088176","title":"重慶市涪陵區市場監管局開展醫療器械網售環節專項檢查","url":"https://stock-news.laohu8.com/highlight/detail?id=2534088176","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534088176?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:39","pubTimestamp":1746779940,"startTime":"0","endTime":"0","summary":"5月9日，执法人员在一家医疗器械销售单位通过检查下单记录检查医疗器械网售情况。中国质量新闻网讯 连日来，重庆市涪陵区市场监管局持续开展了医疗器械网售环节专项检查。此次行动，执法人员通过对各医疗器械销售单位医疗器械网上下单情况及销售记录、医疗器械追溯体系落实情况进行拉网式检查，防止来路不明、质量不合格医疗器械网售行为侵犯消费者的合法权益。（朱小娅 文光辉）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-05-09/doc-inevyhfs7446655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","09996","BK1100","BK1583","BK1222","09997","159883"],"gpt_icon":0},{"id":"2534173533","title":"復星醫藥子公司獲美國FDA批准開展AGA治療臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2534173533","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534173533?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:37","pubTimestamp":1746779855,"startTime":"0","endTime":"0","summary":"5月9日，复星医药发布公告，控股子公司菌济健康获得美国FDA关于LBP-ShC4开展临床试验的批准。公告指出，目前全球尚无用于治疗雄激素脱发的活体生物治疗产品获批上市。尽管获得临床试验批准，但药品研发存在风险，后续的临床研究仍需获得美国药品审评部门的审批，且临床试验可能因安全性和有效性问题而终止。2025年一季度，复星医药实现收入94.20亿元，归母净利润7.65亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509164519a477e291&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509164519a477e291&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1583","BK1515","BK1141","BK1191","BK1593","02196","03347"],"gpt_icon":0},{"id":"2534178159","title":"高視醫療(02407)：人工晶狀體植入系統獲得中國醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2534178159","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534178159?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:37","pubTimestamp":1746779821,"startTime":"0","endTime":"0","summary":"智通财经APP讯，高视医疗 发布公告，近日本公司全资附属公司高视泰靓医疗科技有限公司之“人工晶状体植入系统”已获得由广东省药品监督管理局批准的医疗器械注册证。高视泰靓本次获批的人工晶状体植入系统，主要适用于微小切口白内障手术中的人工晶状体植入手术。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1222","BK1100","09996","02407","159883","BK1583","BK1574","09997"],"gpt_icon":0},{"id":"2534173843","title":"高視醫療(02407.HK)人工晶狀體植入系統獲中國醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2534173843","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534173843?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:36","pubTimestamp":1746779760,"startTime":"0","endTime":"0","summary":"高视医疗(02407.HK) 公布，近日公司全资附属高视泰靓之“人工晶状体植入系统”已获得由广东省药品监督管理局批准的医疗器械注册证。高视泰靓本次获批的人工晶状体植入系统，主要适用于微小切口白内障手术中的人工晶状体植入手术。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20221221155533842_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20221221155533842_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1438958/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1222","09996","159883","02407","09997","BK1574","BK1100","BK1583"],"gpt_icon":0},{"id":"2534178363","title":"分析師：美英達成貿易協議 股市修復出現曙光","url":"https://stock-news.laohu8.com/highlight/detail?id=2534178363","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534178363?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:34","pubTimestamp":1746779649,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"cd1b47a8e889161a5b0813fc983249ba","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1229","BK1542","BK1258","BK1583","09983"],"gpt_icon":0}],"pageSize":20,"totalPage":36,"pageCount":11,"totalSize":718,"code":"91000000","status":"200"}]}}